公开(公告)号：US20220356223A1

公开(公告)日：2022-11-10

申请号：US17621396

申请日：2020-06-23

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Alexander Muik ,  Mathias Vormehr ,  Lena Mareen Kranz

IPC: C07K14/55 ,  A61P35/00

Abstract: The invention relates to variants of interleukin-2 (IL2). In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted such that affinity for the βγ IL2 receptor complex (IL2Rβγ) is enhanced. In one embodiment, the human IL2 or functional variant thereof is further substituted such that affinity for the αβγ IL2 receptor complex (IL2αβγ) is reduced. In one embodiment, the polypeptide activates effector T cells over regulatory T cells. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.

公开(公告)号：US11298426B2

公开(公告)日：2022-04-12

申请号：US15895402

申请日：2018-02-13

Applicant: BioNTech SE

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sebastian Kreiter

IPC: A61K47/64 ,  A61K48/00 ,  C07K14/74 ,  C12N15/62 ,  C12N5/10 ,  C07K14/47 ,  C12N5/0783

Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

公开(公告)号：US11279684B2

公开(公告)日：2022-03-22

申请号：US16644079

申请日：2018-08-31

Applicant: BIONTECH SE

Inventor： Christophe Henry

IPC: A61P35/00 ,  C07D471/04 ,  C07D401/04

Abstract: The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

公开(公告)号：US20210277133A1

公开(公告)日：2021-09-09

申请号：US17172700

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK ,  Christian GRUNWITZ

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20210269541A1

公开(公告)日：2021-09-02

申请号：US17172698

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK ,  Christian GRUNWITZ

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20210246191A1

公开(公告)日：2021-08-12

申请号：US16972794

申请日：2019-06-06

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Bonny Gaby Lui ,  Nadja Salomon ,  Joycelyn Wüstehube-Lausch ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Markus Fiedler

IPC: C07K14/78 ,  C07K1/107 ,  G01N33/68 ,  G01N33/574

Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.

公开(公告)号：US11084882B2

公开(公告)日：2021-08-10

申请号：US16855703

申请日：2020-04-22

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Friederike Gieseke ,  Ugur Sahin

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US12208136B2

公开(公告)日：2025-01-28

申请号：US18186914

申请日：2023-03-20

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin ,  Kayvon Modjarrad

IPC: A61K39/215 ,  A61K9/127 ,  A61K39/145 ,  A61K45/06 ,  A61K47/26 ,  C12N15/86 ,  A61K39/00

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US20250027066A1

公开(公告)日：2025-01-23

申请号：US18708333

申请日：2022-11-09

Applicant: BIONTECH SE

Inventor： Ugur Sahin ,  Andreas Henning ,  Stephanie Erbar ,  Stefan Albrecht Schille ,  Anna Spier ,  Lorenzo Corsini ,  Zehra Visram

IPC: C12N9/36 ,  A61K9/00 ,  A61K9/51 ,  A61P31/04

Abstract: The invention provides agents and methods for treating bacterial infections using RNA. The RNA encoding peptidoglycan hydrolases. e.g., endolysins, is formulated and administered in a way that peptidoglycan hydrolase proteins. e.g., endolysin proteins, can be produced and secreted by cells of a subject to combat bacterial infections.

公开(公告)号：US20250002522A1

公开(公告)日：2025-01-02

申请号：US18702857

申请日：2022-10-21

Applicant: BioNTech SE ,  Consejo Superior de Investigaciones Científicas (CSIC)

Inventor： Jorge Moreno Herrero ,  Heinrich Haas ,  Stephanie Erbar ,  José Manuel García Fernández ,  Juan Manuel Benito Hernández ,  Jose Lopez Fernandez ,  Práxedes Sánchez Mellado

IPC: C07H15/04 ,  C07H1/00

Abstract: The present disclosure provides compositions comprising an oligosaccharide of formula (I), wherein said compositions are useful for delivery of certain agents, including, for example, nucleic acids.